KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Change in Account Payables (2018 - 2025)

Historic Change in Account Payables for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to -$5.4 million.

  • Vir Biotechnology's Change in Account Payables fell 27392.14% to -$5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $106000.0, marking a year-over-year decrease of 9703.5%. This contributed to the annual value of -$988000.0 for FY2024, which is 23497.27% down from last year.
  • As of Q3 2025, Vir Biotechnology's Change in Account Payables stood at -$5.4 million, which was down 27392.14% from $8.9 million recorded in Q2 2025.
  • Vir Biotechnology's 5-year Change in Account Payables high stood at $8.9 million for Q2 2025, and its period low was -$7.5 million during Q3 2023.
  • Its 5-year average for Change in Account Payables is $126947.4, with a median of -$934000.0 in 2023.
  • As far as peak fluctuations go, Vir Biotechnology's Change in Account Payables crashed by 34725.14% in 2021, and later soared by 40622.19% in 2025.
  • Vir Biotechnology's Change in Account Payables (Quarter) stood at $788000.0 in 2021, then surged by 255.33% to $2.8 million in 2022, then decreased by 6.18% to $2.6 million in 2023, then plummeted by 173.7% to -$1.9 million in 2024, then plummeted by 179.03% to -$5.4 million in 2025.
  • Its Change in Account Payables was -$5.4 million in Q3 2025, compared to $8.9 million in Q2 2025 and -$1.4 million in Q1 2025.